Accordingly, the AGE/RAGE axis is reported as a key driver of IBD, and multiple beneficial effects are reported for PPAR-gamma agonists against metabolic syndromes and age-related diseases [43,44,45,46]. This evidence concerns the gene PPARG and inflammatory bowel disease.